FDA rejects Capricor's DMD cell therapy, citing need for more data
Originally Published 6 months ago — by STAT
The FDA rejected Capricor Therapeutics' application for its cell therapy deramiocel aimed at treating Duchenne muscular dystrophy, citing insufficient evidence of effectiveness and requesting more clinical data.